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What calprotectin cut-offs
should apply for IBD in
general practice?
To the Editor
We write in response to the recent
article by Dhaliwal et al1 in Frontline
Gastroenterology, which discussed
the utility of faecal calprotectin (FC)
levels in discriminating between
inflammatory bowel disease (IBD)
and irritable bowel syndrome (IBS).
We applaud the authors’ investiga-
tion of this important topic given the
high prevalence of IBS in general
practice, the understandable concern
of practitioners in reliably excluding
inflammatory conditions in patients
with IBS and the imperative to avoid
unnecessary diagnostic evaluations.
The main reported results of the
Dhaliwal study support previous find-
ings in the published literature that, at
a cut-off of 50 mg/g, FC determin-
ation demonstrates adequate sensitiv-
ity and specificity to distinguish
between IBS and IBD.2 The authors
note, however, that raising the
cut-off to 100 mg/g ‘does further
improve’ sensitivity and specificity of
the FC test, and improves the nega-
tive predictive value (NPV) to 97%
from 87%. This statement highlights
several practical concerns that we
believe are of substantial importance
for both general practitioners and
medical policy decision-makers
when interpreting the extensive lit-
erature on the role of FC in differen-
tiating IBS and IBD.
First, it is essential for readers to
understand which condition (IBS
or IBD) is selected as the ‘target’
when constructing receiver operat-
ing characteristic curves for sensi-
tivity and specificity of FC.
Although the authors state that
‘[performance characteristics] for
diagnosing IBD… were calculated
at different FC cut-off values’, it
appears they actually use IBS as the
target condition for IBS versus IBD
in table 3, as evidenced by the
increase in sensitivity and (slight)
reduction in specificity produced
by raising the cut-off. Using the
authors’ data and switching the
target condition to IBD for an indi-
cation of IBS versus IBD at FC
50 μg/g yields a sensitivity of 77.7
and specificity of 87.5, the inverse
of what is reported in table 3.
Unfortunately, this inconsistency
in selecting the target condition is
not unusual in the published litera-
ture for FC and may contribute to
the widespread perception among
medical policy decision-makers in
the USA that there is a ‘lack of con-
sensus for appropriate cut-off
values for FC’.3
Second, we would like to remind
readers that, unlike sensitivity and
specificity, which are fixed per-
formance characteristics of a test,
the NPV and positive predictive
value (PPV) of a test are dependent
on the prevalence of the target con-
dition in the practitioner’s popula-
tion.4 Although Dhaliwal et al do
not explicitly state the prevalence
figures that they used to calculate
NPV and PPV, it is readily shown
that the authors, by convention,
used the prevalence of IBS and IBD
in their study population (144 of
292 (49%) subjects had Rome II
confirmed IBS; 148/292 (51%) had
IBD) to calculate their reported
predictive values.
However, the prevalence of IBD
and other inflammatory aetiology
of symptoms (cancer, microscopic
colitis, etc.) in patients who meet
Rome III criteria without alarm fea-
tures in a typical general practice
setting is 3% or less.5–8 Since the
primary concern of general practi-
tioners when initially evaluating a
patient with altered bowel patterns
and abdominal pain is to exclude
the presence of these relatively
uncommon but serious organic
inflammatory conditions, a lower
cut-off of 50 is optimal for this
clinical setting because it minimises
false negatives. Therefore, using
Dhaliwal’s sensitivity/specificity
values for IBS versus IBD at FC
50 μg/g (77.7 and 87.5, respect-
ively, when the target condition is
IBD), it can readily be shown that
the NPV of FC in Rome III quali-
fied patients presenting to a general
practitioner is ∼100% (assuming a
1% prevalence of IBD).
It has been shown that much of
the cost attributed to IBS arises
from the time and resources used to
establish the diagnosis and to rule
out inflammatory conditions; 50%–
75% of the overall costs attributable
to IBS arise from the use of invasive
endoscopic procedures.9 10 Like
others, we argue that use of the FC
test, at the manufacturer’s recom-
mended cut-off of 50 mg/g, is clinic-
ally useful and cost-effective, with
little risk of an error that would
pose serious risks.2 Indeed, previous
work has shown that the routine use
of calprotectin to exclude inflam-
matory changes results in substantial
economic savings.2 11
In summary, while we applaud
the work of Dhaliwal et al, in con-
firming the value of FC in the clin-
ical setting where IBD and IBS are
the primary concerns, we caution
that greater insight is required in
the interpretation of such studies,
particularly with regard to estab-
lishment of the target condition
against which test performance
characteristics are measured. We
also reiterate that FC has high clin-
ical utility in general practice set-
tings to exclude IBD or other
inflammatory conditions of the
colon, is Food and Drug
Administration (FDA)-cleared for
this indication, and is also recom-
mended by National Institute for
Health and Clinical Excellence
(NICE) guidelines and several
gastrointestinal (GI) specialty soci-
eties for this purpose.
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